March 27 (Reuters) - Novocure said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer. (Reporting by Puyaan Singh in Bengaluru; Editing by Shounak Dasgupta)
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog.
Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?
The U.S. birth rate from 2023 was down 2% from 2022, according to the Centers for Disease Control and Prevention.
With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.